No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients (2022)
- Authors:
- USP affiliated authors: BOLLELA, VALDES ROBERTO - FMRP ; ROCHA, ADRIANA - FCFRP ; LANCHOTE, VERA LUCIA - FCFRP ; NARDOTTO, GLAUCO HENRIQUE BALTHAZAR - FCFRP
- Unidades: FMRP; FCFRP
- DOI: 10.1111/cts.13169
- Subjects: HIV; FARMACOCINÉTICA; TUBERCULOSE; ESTUDOS PROSPECTIVOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Clinical and Translational Science
- ISSN: 1752-8054
- Volume/Número/Paginação/Ano: v. 15, p. 514-523, 2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
- Licença: cc-by-nc-nd
-
ABNT
NARDOTTO, Glauco Henrique Balthazar et al. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science, v. 15, p. 514-523, 2022Tradução . . Disponível em: https://doi.org/10.1111/cts.13169. Acesso em: 03 out. 2024. -
APA
Nardotto, G. H. B., Bollela, V. R., Rocha, A., Della Pasqua, O., & Lanchote, V. L. (2022). No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science, 15, 514-523. doi:10.1111/cts.13169 -
NLM
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ; 15 514-523.[citado 2024 out. 03 ] Available from: https://doi.org/10.1111/cts.13169 -
Vancouver
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ; 15 514-523.[citado 2024 out. 03 ] Available from: https://doi.org/10.1111/cts.13169 - Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort
- Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers
- Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers
- Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia
- Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics
- Omeprazole inhibits preferentially the metabolism of the (+)-(S)-citalopram eutomer in healthy volunteers
- P-Glycoprotein and organic anion transporter polypeptide 1B/breast cancer resistance protein drug transporter activity in pregnant women living with HIV
- Farmacocinética-farmacodinâmica dos enantiômeros do carvedilol em voluntários sadios e em pacientes portadores de diabetes mellitus tipo 2
- Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers
- UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers
Informações sobre o DOI: 10.1111/cts.13169 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
